We are transforming the lives of patients by developing best-in-class treatments for fibrotic diseases.
fibrosis β’ integrins β’ muscle biology β’ oncology β’ Duchenne muscular dystrophy
51 - 200
π° $287.5M Post-IPO Equity on 2023-01
April 5
π’ In-office - San Francisco
π΅ $160k - $170k / year
β° Full Time
π Senior
π Data Scientist
π H1B Visa Sponsor